mPhase Technologies’ Smart Drug Delivery System Holds Significant Portion of Patentable Claims

CLIFTON, N.J.--()--mPhase Technologies, Inc. (XDSL) (http://mphasetech.com/), announced an update on the Drug Delivery System patent application which was originally filed in February of 2013. The Drug Delivery System is based on mPhase Technologies’ award winning advanced battery technology. Frost and Sullivan recognized mPhase with its’ 2013 North American Advanced Battery Technology Innovation Award for Best Practices.

In December of 2013 the patent application for the Smart Drug Delivery System received a first review (Office Action) by the United States Patent and Trademark Office. The patent office examiner indicated that a significant portion of the claims were patentable. A response to the office was filed, without amending the claims, but with strong arguments as to why all of the claims are patentable. mPhase is now waiting for a response from the patent office which is expected no later than in the first quarter of 2015.

mPhase believes the issuance of a patent could lead to licensing opportunities for the novel drug delivery system, possibly creating greater shareholder value. The drug delivery patent if issued, would enable the automatic dispensing of a pre-set dosage of a drug agent or medication.

The field of invention relates to a drug delivery system that generally includes a housing having one or more reservoirs; each having a medical agent hermetically sealed therein. A membrane extends across each of the one or more reservoirs which is adapted to allow the medical agents to pass through in response to external stimuli, such as physical puncturing, melting the membranes through use of heating elements or electrowetting in response to a voltage pulse. A wicking material extends across the membranes through which the medical agents are dispensed to a patient. Because the housing can be made flat, the overall dispensing device can be reduced in size, allowing the drug delivery device to be located and attached to broader areas of the patient’s body for expanded medical applications and treatment.

Under past Cooperative Research and Development Agreements with the United States Army, mPhase developed a smart nano battery that made it possible to keep the essential components of a battery, the solid electrode and liquid electrolyte, separated until power is needed. This battery system can be activated electronically, mechanically or via gravitational pull.

About mPhase Technologies, Inc. mPhase Technologies Inc. (XDSL), a 2013 Frost and Sullivan recipient for the North American Advanced Battery Technology Innovation Award. mPhase Technologies is a publicly traded company (XDSL) that is pioneering a revolutionary Smart Surface technology enabled by breakthroughs in nanotechnology, MEMS processing and microfluidics. Our Smart Surface technology has potential applications within drug delivery systems, lab-on-a-chip analytic systems, self-cleaning systems, liquid and chemical sensor systems, and filtration systems. mPhase has pioneered its first Smart Surface enabled product, the mPhase Smart NanoBattery, still in development. More information about the company can be found at http://www.mPhaseTech.com.

About mPower Technologies

mPower Technologies Inc. is the wholly owned consumer products subsidiary of mPhase Technologies, Inc. More information about the company can be found at http://www.mpowertech.com.

Forward-Looking Statements. As a cautionary note to investors, certain matters discussed in this press release may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such matters involve risks and uncertainties that may cause actual results to differ materially, including the following: changes in economic conditions; general competitive factors; acceptance of the Company's products in the market; the Company's success in technology and product development; the Company's ability to execute its business model and strategic plans; and all the risks and related information described from time to time in the Company's SEC filings, including the financial statements and related information contained in the Company's SEC Filing. mPhase assumes no obligation to update the information in this release.

Contacts

mPhase Technologies, Inc.
Danielle LaSalle, 973-256-3737
dlasalle@mPhasetech.com

Release Summary

Smart Drug Delivery System

Contacts

mPhase Technologies, Inc.
Danielle LaSalle, 973-256-3737
dlasalle@mPhasetech.com